Benzinga -
- Citigroup (NYSE:C) raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday.
- HC Wainwright & Co. cut ImmunoGen, Inc. (NASDAQ: IMGN) price target from $20 to $15. HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a Buy rating on the stock. ImmunoGen dropped 7.4% to trade at $4.78 on Friday.
- B. Riley Securities raised TG Therapeutics, Inc. (NASDAQ: TGTX) price target from $17 to $23. B. Riley Securities analyst Mayank Mamtani maintained a Buy rating on the stock. TG Therapeutics shares rose 1.5% to trade at $10.56 on Friday.
- Cantor Fitzgerald slashed the price target on Cresco Labs Inc. (OTC: CRLBF) from $15 to $14.25. Cantor Fitzgerald analyst Pablo Zuanic maintained an Overweight rating on the stock. Cresco Labs shares gained 1.4% to trade at $1.86 on Friday.
- HC Wainwright & Co. cut Agile Therapeutics, Inc. (NASDAQ: AGRX) price target from $5 to $3. HC Wainwright & Co. analyst Oren Livnat maintained a Buy rating on the stock. Agile Therapeutics shares fell 4.2% to $0.1912 on Friday.
- Cantor Fitzgerald cut Curaleaf Holdings, Inc. (OTC: CURLF) price target from $13 to $12. Cantor Fitzgerald analyst Pablo Zuanic maintained an Overweight rating on the stock. Curaleaf shares fell 1.5% to trade at $4.02 on Friday.
- Argus Research raised Hormel Foods Corporation (NYSE: NYSE:HRL) price target from $53 to $54. Argus Research analyst Taylor Conrad maintained a Buy rating on the stock. Hormel Foods shares fell 0.1% to close at $45.44 on Friday.
- Maxim (NASDAQ:MXIM) Group cut Euroseas Ltd. (NASDAQ: ESEA) price target from $42 to $36. Maxim Group analyst Tate Sullivan maintained a Buy rating on the stock. Euroseas shares fell 1.6% to close at $18.40 on Friday.
- Evercore ISI Group increased TG Therapeutics, Inc. (NASDAQ: TGTX) price target from $11 to $16. Evercore ISI Group analyst Joshua Schimmer maintained an Outperform rating on the stock. TG Therapeutics shares rose 1.5% to trade at $10.56 on Friday.
- EF Hutton reduced Hoth Therapeutics, Inc. (NASDAQ: HOTH) price target from $45 to $33. EF Hutton analyst Constantine Davides maintained a Buy rating on the stock. Hoth Therapeutics shares fell 26.3% to $7.90 on Friday.
- Goldman Sachs (NYSE:GS) raised TG Therapeutics, Inc. (NASDAQ: TGTX) price target from $4 to $6. Goldman Sachs analyst Corinne Jenkins maintained a Sell rating on the stock. TG Therapeutics shares rose 1.5% to trade at $10.56 on Friday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.